These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Therapeutic use of fresh plasma and "virus-safe" plasma]. Seyfert UT; Lorenz C; Espig J; Heinrich H; Grund S; Rupp KH; Wenzel E Beitr Infusionsther; 1991; 28():35-48. PubMed ID: 1725654 [TBL] [Abstract][Full Text] [Related]
3. [Techniques of security of plasma transfusion]. Huart JJ Cah Anesthesiol; 1994; 42(3):433-4. PubMed ID: 7812877 [TBL] [Abstract][Full Text] [Related]
4. Results of a quality-control study of lyophilized pooled plasmas which have been 'virally inactivated' using a solvent detergent method (modified Horowitz procedure). Trobisch H Beitr Infusionsther; 1991; 28():92-109. PubMed ID: 1725667 [TBL] [Abstract][Full Text] [Related]
5. [The innocuity of stable products derived from human plasma]. Subtil E Contracept Fertil Sex; 1993 Nov; 21(11):836. PubMed ID: 8281234 [No Abstract] [Full Text] [Related]
6. Reducing the risk of infection from plasma products: specific preventative strategies. Burnouf T; Radosevich M Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252 [TBL] [Abstract][Full Text] [Related]
7. Update on pathogen reduction technology for therapeutic plasma: an overview. Solheim BG; Seghatchian J Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528 [TBL] [Abstract][Full Text] [Related]
8. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602 [TBL] [Abstract][Full Text] [Related]
9. Solvent/detergent-treated plasma: a tale of 30 years of experience. Liumbruno GM; Marano G; Grazzini G; Capuzzo E; Franchini M Expert Rev Hematol; 2015 Jun; 8(3):367-74. PubMed ID: 25695198 [TBL] [Abstract][Full Text] [Related]
10. Risks and side effects of therapy with plasma and plasma fractions. MacLennan S; Barbara JA Best Pract Res Clin Haematol; 2006; 19(1):169-89. PubMed ID: 16377549 [TBL] [Abstract][Full Text] [Related]
11. A probabilistic model for analyzing viral risks of plasma-derived medicinal products. Janssen MP; Over J; van der Poel CL; Cuijpers HT; van Hout BA Transfusion; 2008 Jan; 48(1):153-62. PubMed ID: 17894786 [TBL] [Abstract][Full Text] [Related]
15. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination. Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953 [TBL] [Abstract][Full Text] [Related]
16. [Preliminary results of a prospective randomized clinical study on the comparison of solvent- and detergent-inactivated plasma (SDP-TNBT/Triton X-100) and untreated fresh-frozen plasma]. Mortelmans Y; Beck KH; Kretschmer V Beitr Infusionsther Transfusionsmed; 1994; 32():419-21. PubMed ID: 9480136 [TBL] [Abstract][Full Text] [Related]
17. [Indications for labile blood products]. Jeanne M; Rasonglès P Rev Prat; 2001 Jun; 51(12):1318-27. PubMed ID: 11503505 [TBL] [Abstract][Full Text] [Related]
18. Virus safety of pooled fresh-frozen plasma inactivated by solvent/detergent treatment. Prince AM; Horowitz B Beitr Infusionsther; 1993; 31():21-4. PubMed ID: 7693256 [No Abstract] [Full Text] [Related]